Our research and development is currently focused on the stimulation of hair growth and diabetes. Following our basic research related to arteriosclerosis our founders observed an increased hair growth in mice, from the modified human protein, osteopontin. The research has since been focused on human proteins from which we develop our drug candidates. The peptide in the lead of our research, FOL-005, has significantly shown effects on human hair growth.
Hair loss and unwanted hair growth affects millions of people around the world, both men and women. In many cases this is traumatic for the individual concerned. There are no really, effective treatments on the market today – and those products that are available do not suit both men and women. In short, there is a considerable demand for medications which are both effective and with few unwanted side-effects. Having said this, there is a large number of patients getting no treatment at all.
In our continued research about the mechanisms of human proteins, another peptide, FOL-014, has shown to increase the release of insulin from the pancreas in pre-clinical studies. This may be a game-changer for the treatment of diabetes patients. Follicum is participating in a comprehensive R&D cooperation in diabetes with the University of Lund (Lund University Diabetes Centre) and several strong partners in this area.